Leerink Partners Upgrades Amneal Pharmaceuticals (NASDAQ:AMRX) to “Strong-Buy”

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by analysts at Leerink Partners to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. restated an “overweight” rating and set a $22.00 target price on shares of Amneal Pharmaceuticals in a research report on Wednesday, August 26th. The Goldman Sachs Group reissued a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research note on Friday, July 31st. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. Finally, Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $19.57.

Amneal Pharmaceuticals Stock Performance

Shares of Amneal Pharmaceuticals stock opened at $17.25 on Wednesday. The firm has a fifty day moving average of $17.77 and a two-hundred day moving average of $15.01. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock has a market capitalization of $5.51 billion, a price-to-earnings ratio of 35.20 and a beta of 1.24. Amneal Pharmaceuticals has a 52 week low of $9.49 and a 52 week high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, July 30th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, equities research analysts predict that Amneal Pharmaceuticals will post 0.94 EPS for the current year.

Insider Transactions at Amneal Pharmaceuticals

In other news, EVP Nikita Shah sold 146,403 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares of the company’s stock, valued at $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jason Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the transaction, the executive vice president owned 35,171 shares in the company, valued at $611,975.40. This trade represents a 85.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 413,016 shares of company stock valued at $7,216,567 over the last 90 days. 17.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Kemnay Advisory Services Inc. acquired a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at approximately $26,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Amneal Pharmaceuticals during the second quarter worth $29,000. Federated Hermes Inc. raised its holdings in shares of Amneal Pharmaceuticals by 1,680.6% during the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after acquiring an additional 2,168 shares during the period. Comerica Bank lifted its position in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares in the last quarter. Finally, Transamerica Financial Advisors LLC lifted its position in Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.